Press Releases

Interim report January – September 2022

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2022

Nomination Committee Appointed for the Annual General Meeting 2023 in Promore Pharma

Promore Pharma provides an update on the Phase II clinical trial with ensereptide

Promore Pharma Interim report January – June 2022

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Second Quarter 2022

Promore Pharma granted EU patent regarding treatment of chronic wounds

The last clinic visit conducted in Promore Pharma’s phase II study of ensereptide

Report from the Annual General Meeting of Promore Pharma AB held on 17 May 2022

Promore Pharma — interim report January-March 2022

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2022

Promore Pharma’s Annual Report 2021 and AGM related Documents Published

NOTICE OF ANNUAL GENERAL MEETING PROMORE PHARMA AB (PUBL)

Promore Pharma has reached recruitment goal in clinical trial of ensereptide

Interim report January – December 2021

First patient recruited to Promore Pharma’s clinical trial regarding scarring according to plan

Invitation to Conference Call regarding Promore Pharma’s Year-end Report 2021

Promore Pharma deregisters warrants